FDAsafety guidance83% confidence
April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (melanoma) as melanoma patients.
Regulatory Analysis
April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Supporting Context
- Therapeutic area
- Oncology · Melanoma
- Sub-indication
- Melanoma
Related signal: Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study